GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX 2,031.00
0.00 (0.00%)
At close: Mar 13, 2026
GSK plc Revenue
GSK plc had revenue of 8.62B GBP in the quarter ending December 31, 2025, with 6.17% growth.
Revenue (ttm)
32.67B
Revenue Growth
+4.11%
P/S Ratio
2.49
Revenue / Employee
488.73K
Employees
66,841
Market Cap
81.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| Hikma Pharmaceuticals | 2.49B |
| Convatec Group | 1.81B |
| Spire Healthcare Group | 1.58B |
| CVS Group | 692.80M |
| Genus | 672.00M |
GSK plc News
- 12 hours ago - GSK and Amgen to add medicines to TrumpRx, Fox Business reports - Reuters
- 20 hours ago - FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Benzinga
- 21 hours ago - GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk - Business Wire
- 22 hours ago - GSK Says FDA Expands Arexvy RSV Vaccine Approved Age To Adults 18 To 49 Years At Increased Risk - Nasdaq
- 1 day ago - GSK gets US FDA approval for expanded use of RSV vaccine - Reuters
- 2 days ago - BioVersys Doses First Patient In Phase 2b Of AlpE - Nasdaq
- 2 days ago - GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency - GuruFocus